Home / Ingredients / Coenzyme Q10 (CoQ10)
Evidence reviewed: 2026-10-02
Condition-specific evidence is mixed; recent meta-analyses suggest possible benefits in heart failure and statin-associated muscle symptoms, but certainty varies and broad energy or prevention claims are not established.
Recent meta-analyses report favorable outcomes for some heart-failure endpoints and a possible reduction in statin-associated muscle pain, while other reviews have found inconsistent or null effects. Evidence differs by condition, formulation, dose, and study quality, so CoQ10 should not be presented as a general cardiovascular or energy enhancer.
Clinical studies vary widely in dose, disease population, formulation, and treatment duration. CoQ10 presence in a multi-ingredient product is not enough to infer a studied clinical effect.
Serious adverse effects are uncommon in available data, but mild insomnia or digestive symptoms can occur. CoQ10 may interact with warfarin, insulin, and some cancer treatments.
NOURISH+, V-DAILY, VITALPRO, and V-DAILY SACHET list CoQ10 but do not publish a study-matched dose. Finished-product cardiovascular, energy, or statin-related claims remain unverified.
Efficacy and safety of coenzyme Q10 in heart failure: a meta-analysis of randomized controlled trials (Meta-analysis of randomized controlled trials; PMID 39462324)
Population/scope: 33 randomized studies in people with heart failure
Evidence scope: Mortality, hospitalization, functional status, biomarkers, and exercise capacity
Finding: The pooled analysis reported lower all-cause mortality and heart-failure hospitalization and improvement in some functional outcomes.
Limitations: Evidence quality varied by endpoint and the authors noted small studies and variable study quality; findings apply to heart-failure populations, not general cardiovascular prevention or energy claims.
Directness: Relevant human evidence · verified 2026-10-02
Effects of coenzyme Q10 supplementation on myopathy in statin-treated patients: a systematic review and meta-analysis (Systematic review and meta-analysis of randomized controlled trials; PMID 41158831)
Population/scope: 7 randomized trials; 389 statin-treated adults
Evidence scope: Statin-associated muscle pain
Finding: The pooled analysis found a modest reduction in muscle-pain intensity with CoQ10.
Limitations: Only seven small trials were included, treatment durations were short, and results were mixed across individual trials; more research is needed.
Directness: Relevant human evidence · verified 2026-10-02
Important: Ingredient-level evidence is not proof that a finished product has the same effect. Dose, form, population, duration, and formulation must match.
For informational purposes only; not individualized medical advice.